Key result
The T-MACS decision aid rules out acute coronary syndrome in 40.4% of emergency department patients using a single high-sensitivity cardiac troponin T test with 98.8% sensitivity and 99.7% NPV.
Why the study?
Does the T-MACS clinical prediction model and high-sensitivity troponin testing improve early rule-out and rule-in of acute coronary syndromes compared to standard serial testing in Emergency Department chest pain patients?
Does the T-MACS clinical prediction model and high-sensitivity troponin testing improve early rule-out and rule-in of acute coronary syndromes compared to standard serial testing in Emergency Department chest pain patients?
Answers are grounded in this paper and cite their sources.
This review highlights how combining single-sample high-sensitivity troponin with continuous multivariable machine-learning prediction models like T-MACS can safely accelerate ACS diagnosis and enable personalized shared decision-making in the emergency department.
Chest pain accounts for approximately 6% of Emergency Department (ED) attendances and is the most common reason for emergency hospital admission. For many years, our approach to diagnosis has required patients to stay in hospital for at least 6-12 h to undergo serial biomarker testing. As less than one fifth of the patients undergoing investigation actually has an acute coronary syndrome (ACS), there is tremendous potential to reduce unnecessary hospital admissions. Recent advances in diagnostic technology have improved the efficiency of care pathways. Decision aids such as the Thrombolysis in Myocardial Infarction (TIMI) risk score and the History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score enable rapid 'rule out' of ACS within hours of patients arriving in the ED. With high sensitivity cardiac troponin (hs-cTn) assays, approximately one third of patients can have ACS 'ruled out' with a single blood test, and up to two thirds could have an acute myocardial infarction 'ruled out' with a second sample taken after as little as 1 h. Building on those recent advances, this paper presents an overview of the principles behind the development of the Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid. This clinical prediction model could be used to 'rule out' and 'rule in' ACS following a single blood test and to calculate the probability of ACS for every patient. The future potential of this approach is then addressed, including practical applications of artificial intelligence, shared decision making, near-patient testing and personalized medicine.
No takes yet. Share an insight, caveat, or question.
Richard Body (2018) conducted a review in Suspected acute coronary syndromes (ACS). Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid and high-sensitivity cardiac troponin (hs-cTn) algorithms vs. Standard serial biomarker testing over 6-12 hours or existing risk scores (TIMI, HEART, EDACS) was evaluated on Diagnostic rule-out and rule-in of acute coronary syndromes (ACS). The T-MACS decision aid rules out acute coronary syndrome in 40.4% of emergency department patients using a single high-sensitivity cardiac troponin T test with 98.8% sensitivity and 99.7% NPV.
Synapse has enriched 10 related papers. Consider them for comparative context: